MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung Cancer

Loading news article.

MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung Cancer | WAPE

MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung Cancer

Article summary

Related companies

Comments —